Patents Assigned to IGM BIOSCIENCES, INC.
-
Patent number: 11639389Abstract: The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.Type: GrantFiled: September 30, 2016Date of Patent: May 2, 2023Assignee: IGM Biosciences, Inc.Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
-
Patent number: 11578131Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.Type: GrantFiled: April 28, 2020Date of Patent: February 14, 2023Assignee: IGM Biosciences, Inc.Inventors: Beatrice Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
-
Patent number: 11555075Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.Type: GrantFiled: September 19, 2018Date of Patent: January 17, 2023Assignee: IGM Biosciences, Inc.Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
-
Patent number: 11542342Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.Type: GrantFiled: January 16, 2020Date of Patent: January 3, 2023Assignee: IGM Biosciences, Inc.Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
-
Patent number: 11535664Abstract: This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.Type: GrantFiled: February 19, 2020Date of Patent: December 27, 2022Assignee: IGM Biosciences, Inc.Inventors: Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
-
Publication number: 20220267415Abstract: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).Type: ApplicationFiled: February 15, 2022Publication date: August 25, 2022Applicants: The Board of Regents of The University of Texas System, IGM Biosciences, Inc.Inventors: Zhiqiang KU, Xuping XIE, Paul HINTON, Ningyan ZHANG, Bruce KEYT, Dean NG, Stephen CARROLL, Pei-Yong SHI, Zhiqiang AN
-
Patent number: 11401337Abstract: The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the C?3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.Type: GrantFiled: April 6, 2018Date of Patent: August 2, 2022Assignee: IGM Biosciences, Inc.Inventors: Ramesh Baliga, Dean Ng
-
Patent number: 11192941Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.Type: GrantFiled: January 7, 2020Date of Patent: December 7, 2021Assignee: IGM Biosciences, Inc.Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
-
Patent number: 10975147Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.Type: GrantFiled: February 27, 2020Date of Patent: April 13, 2021Assignee: IGM Biosciences, Inc.Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
-
Patent number: 10954302Abstract: Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.Type: GrantFiled: May 9, 2017Date of Patent: March 23, 2021Assignee: IGM Biosciences, Inc.Inventors: Bruce Keyt, Leonard George Presta, Ramesh Baliga
-
Patent number: 10899835Abstract: This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.Type: GrantFiled: March 23, 2020Date of Patent: January 26, 2021Assignee: IGM Biosciences, Inc.Inventors: Ramesh Baliga, Bruce Keyt, Dean Ng
-
Patent number: 10822399Abstract: The present invention concerns IgA multi-specific binding molecules. In particular, the invention concerns multi-specific, including bispecific, binding molecules comprising IgA heavy chain sequences, and methods for their preparation and use.Type: GrantFiled: February 10, 2015Date of Patent: November 3, 2020Assignee: IGM Biosciences, Inc.Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Stephen F. Carroll
-
Patent number: 10787520Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.Type: GrantFiled: March 4, 2016Date of Patent: September 29, 2020Assignee: IGM Biosciences, Inc.Inventors: Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
-
Patent number: 10689449Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.Type: GrantFiled: January 20, 2016Date of Patent: June 23, 2020Assignee: IGM Biosciences, Inc.Inventors: Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Alan Keyt, Ramesh Baliga
-
Patent number: 10618978Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.Type: GrantFiled: September 30, 2016Date of Patent: April 14, 2020Assignee: IGM Biosciences, Inc.Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
-
Patent number: 10604559Abstract: This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.Type: GrantFiled: March 25, 2016Date of Patent: March 31, 2020Assignee: IGM Biosciences, Inc.Inventors: Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
-
Patent number: 10570191Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.Type: GrantFiled: April 15, 2016Date of Patent: February 25, 2020Assignee: IGM Biosciences, Inc.Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
-
Patent number: 10400038Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.Type: GrantFiled: April 2, 2015Date of Patent: September 3, 2019Assignee: IGM Biosciences, Inc.Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
-
Patent number: 10351631Abstract: The present invention concerns binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same. The invention further concerns multi-specific binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same.Type: GrantFiled: September 4, 2014Date of Patent: July 16, 2019Assignee: IGM BIOSCIENCES, INC.Inventors: Bruce Alan Keyt, Fen Zhang, Leonard George Presta, Rency Yoshimura
-
Publication number: 20190100597Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.Type: ApplicationFiled: March 4, 2015Publication date: April 4, 2019Applicant: IGM Biosciences, Inc.Inventors: Bruce Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang